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Abstract: 
Tuberculosis is one of the leading contagious diseases, caused by Mycobacterium 
tuberculosis. Despite improvements in anti-tubercular agents, it remains one of the most 
prevalent infectious diseases worldwide, responsible for a total of 1.6 million deaths 
annually. The emergence of multidrug resistant strains highlighted the need of discovering 
novel drug targets for the development of anti-tubercular agents. 2-C-methyl-D-erythritol-4-
phosphate cytidyltransferase (IspD) is an enzyme involved in MEP pathway for isoprenoid 
biosynthesis, which is considered as an attractive target for the discovery of novel antibiotics 
for its essentiality in bacteria and absence in mammals. In the present study, we have 
employed structure based drug design approach to develop novel and potent inhibitors for 
IspD receptor. To explore binding affinity and hydrogen bond interaction between the ligand 
and active site of IspD receptor, docking studies were performed. ADMET and synthetic 
accessibility filters were used to screen designed molecules. Finally, ten compounds were 
selected and subsequently submitted for the synthesis and in vitro studies as IspD inhibitors.  
Keywords: ADMET, Anti-tubercular agents, De novo design, IspD inhibitors, Synthetic 
accessibility  
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1. Introduction  
Mycobacterium tuberculosis (MTB), the causative organism of tuberculosis, is ranked the 
leading bacterial infectious agent [1, 2]. World Health Organization reported that there were 
about 6,50,000 cases of multidrug-resistant TB (MDR-TB) present in the world in 2010 and it 
is estimated that within 2020, approximately 1000 million people will be newly infected, over 
150 million people will get sick, and 36 million will die of TB if proper control measures are 
not established [3]. Furthermore, the emergence of MDR-TB and extensively drug-resistant 
(XDR) TB is paving the way for almost untreatable tuberculosis. Therefore, the development 
of new drugs for the treatment of MDR-TB, XDR-TB, and latent TB is a priority task [4, 5]. 
As these drugs have to be selective for Mycobacteria, effective against drug resistant strains, 
and compatible with HIV-1 drugs, a novel mode of action is necessitated [6, 7]. 
Polyprenyl phosphate, an isoprenoid, carries activated sugar for the biosynthesis of 
arabinogalactan, arabinomannan and lipoarabinomannan (LAM), thereby supporting cell wall 
synthesis in Mycobacterium [8]. The side chain of menaquinone, a component of the electron 
transport chain of M.tuberculosis, is also derived from polyprenyl diphosphate. Thus, 
isoprenoids are vital for the survival of M.tuberculosis. Isopentenyl diphosphate (IPP) and 
dimethylallyl diphosphate (DMAPP), which are synthesized via the methylerythritol 
phosphate (MEP) pathway, participate in the generation of isoprenoids in eubacteria [9]. 
Many enzymes are involved in MEP pathway, of which 4-diphosphocytidyl-2-C-methyl-D-
erythritol synthase (IspD) encoded by the Rv3852c gene is vital for the growth of MTB [10]. 
The IspD protein is a very promising drug target for anti-tuberculosis drugs as no ortholog of 
MTB IspD exists [10].  
 In the present study, we have employed structure based de novo design approach to 
design novel and potent inhibitors for IspD. Binding affinity and hydrogen bond interactions 
between the ligand and active site of IspD were explored by docking studies. Designed 
molecules were screened for ADMET and SYLVIA score. Finally, ten different molecules 
were selected as IspD inhibitors and subsequently submitted for synthesis and in vitro 
analysis. 
2. Material and Methodology 
2.1. De novo ligand design by LigBuilder 
The overall work flow followed during the designing of IspD inhibitors is as shown in Fig. 1.  
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 Fig. 1. The work flow followed during the designing of IspD inhibitors. 
LigBuilder1.2[11] follows genetic algorithm to design ligands within the active site. It is 
based on 3D structure of the target protein. The binding affinities were scored using empirical 
scoring function. The bioavailability of the designed ligands was predicted using a set of 
chemical rules. The fitness score of the molecule is influenced by binding affinity and 
chemical viability. New molecules were designed from seed structure(s) within the active site 
of IspD. Pocket, grow and process modules were used for the analysis of the active site of the 
target and also in the preparation of input files for the designing of inhibitors. We set the 
parameters as MW: 200-500; logP: 5 to 8; Hbond donor: 1-5; Hbond acceptor: 1 to 10, for 
designing the novel ligands. 
2.2. Molecular docking 
Molecular docking studies were carried out to calculate binding affinities, to screen and to 
investigate the intermolecular interactions between ligands and active site residues of target 
protein. The binding affinities of known inhibitors were compared and, the new ligands were 
screened based on their interactions with amino acids of the active site. Input files for 
molecular docking analysis were generated using Protein Preparation Wizard and LigPrep 
modules. Hydrogen atoms were added to target, the protonation states for histidine residues 
were optimized and the hydrogen atom was minimized up to 0.30Å RMSD using the Protein 
Preparation Wizard. A grid of 10Å around the ligand centre was generated by Receptor Grid 
Generation tool using the prepared protein structure [12]. Extra precision (XP) Glide 
algorithm was validated by re-docking the co-crystallized inhibitor into the grid of target. 
Energy minimization of designed ligands was done using LigPrep with the OPLS_2005 force 
field [13]. Using the grid of the target protein, the XP mode of docking was repeated for each 
designed hit molecule using the grid of the target protein, as described above. The default 
settings for scaling the van der Waals radii were selected: a scaling factor of 0.8 and a partial 
charge cut-off of 0.25 with no constraints were defined during docking process [14].  
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2.3. Synthesis accessibility prediction 
Synthesis accessibility of the designed compounds is a major factor to be determined in de 
novo designing. SYLVIA[15] software was used to determine the synthesis accessibility of 
our prioritized newly generated compounds. SYLVIA scores of compound range from 1 
(easy to synthesize) to 10 (difficult to synthesize) based on synthesis accessibility. Different 
structural complexity measures, different measures of similarity to available starting material 
and retro synthetic reaction fitness were considered in this scoring function. 
2.6. Similarity search 
To confirm novelty in the screened hits similarity search was performed using PubChem and 
SciFinder scholar search tools. The compounds which showed partial similarity to hits were 
subjected to screening process using the molecular docking studies with the same parameters 
which were used to select the hit molecules from the virtual hits. 
3. Results and Discussion 
3.1 Design of new ligands 
In our attempt of structure based de novo design of novel IspD inhibitors, we referred to the 
insights of molecular docking and pharmacophoric features. LigBuilder was implemented for 
designing of novel and potent inhibitors in the active site of IspD. It helps in analyzing the 
active site of the receptor and to derive the key interaction sites, which were further used for 
designing of new molecules based on the seed structure using grow strategy. From the 
literature source we found most of the anti-tubercular agents to be less potent against whole 
cells when compared to that against the purified protein in vivo [16]. This difference in 
activity might be due to the cell wall permeability factor in the whole cells. Thus, it is 
necessary that inhibitors have high permeability and there by its potency against whole cells 
will increase. Therefore, we have set logP values to 5-8. Genetic algorithm population size 
was set to 30000, and 200 genetic generations were carried out for designing new inhibitors. 
Fig. 2 shows the seed structure (aminopyrimidine) with growing points. A total of, 400 new 
compounds were generated by the grow strategy of LigBuilder from seed structures.   
 
Fig. 2. The seed structure along with growing points used for designing novel IspD inhibitors  
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3.2. Molecular docking 
The molecular docking analysis was performed using Glide5.5[14] to prioritize the designed 
virtual hits and subsequently to identify the false positives hits. All designed compounds were 
docked into the active site of IspD, and top 131 virtual hits have shown the similar binding 
pattern as that of the co-crystallized ligand. Fig. 3 shows the docking of the top virtual hit 
(compound 1) with docking score of -7.559 into the active site. It has shown binding to the 
hinge region by forming H-bonds with the peptide backbone of Arg20 and Lys215. It has also 
shown additional hydrogen bond with Thr86. Top virtual hits were showing numerous π-π 
interactions, most notably with Lys27 and Arg83 residue in the hydrophobic pocket.  
 
Fig. 3. The binding pocket of IspD (PDB ID: 2XWN) with docked conformation of the top virtual hit. 
 The molecules were further screened for ADMET properties using Accelrys 
Discovery Studio2.5[17] and Derek2.0 [18]. The synthetic accessibility of 34 prioritized 
designed virtual hits after ADMET analysis was evaluated by SYLVIA software. 26 
compounds were showing SYLVIA score below 6, which suggests that all these compounds 
are easy to synthesize. After carefully analyzing the ADMET properties of 26 compounds 
obtained from docking and synthetic accessibility analysis, we finally considered 10 hits, 
which were not showing any toxicity or less toxicity as predicted by DEREK (Fig. 4). The 
Glide score, SYLVIA score, and LogP values of top ten virtual hits were as shown in Table 1.   
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Table 1. The Glide Score, SYLVIA Score and LogP values of top ten virtual hits. 
Compound  Glide  Score SYLVIA Score LogP 
1 -7.827 5.88 5.52 
2 -6.854 4.76 5.43 
3 -6.773 5.69 5.19 
4 -6.764 5.68 5.16 
5 -6.611 5.88 5.87 
6 -6.526 5.03 5.41 
7 -6.466 4.94 5.26 
8 -6.337 5.69 5.29 
9 -6.314 5.99 6.06 
10 -6.164 4.64 6.25 
 
 The PubChem search tool was used to confirm the novelty of the designed hits. The 
docking scores for the virtual hits were far superior to that of the partially similar compounds. 
Molecular docking studies also proved that these compounds were not suitable to form 
hydrogen bond interactions with the critical amino acid residues like Arg20 and Lys215. The 
novelty of the top virtual hit was further confirmed by the SciFinder scholar search tool. 
Hence, we suggest that these top virtual hits with diverse scaffolds are novel as IspD 
inhibitors. 
 
Fig. 4. The chemical structure of the top ten designed virtual hits.  
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4.  Conclusions 
In this study, we applied structure based drug design approach to develop IspD inhibitors as 
anti-tubercular agent using LigBuilder1.2. The designed virtual hits were selected as positive 
hits based on the molecular docking analysis. ADMET and SYLVIA score analysis were 
performed to identify top virtual hits as IspD inhibitors. Novelty of top designed virtual hits 
was confirmed with PubChem and SciFinder scholar search tools. Combining all these 
results, ten virtual hits were presented as possible lead candidates to be used as novel and 
potent IspD inhibitors. Further in vitro testing of hit compounds would be necessary to 
confirm the success rate of this work and to optimize the hits subsequently. 
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